Approvable generic carbamazepine formulations may not be bioequivalent in target patient populations

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 6, 2013, Pages 525-528

  Tothfalusi, Laszlo ^a   Endrenyi, Laszlo ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antiepileptics; Autoinduction; Bioequivalence; Carbamazepine; Therapeutic equivalence

Indexed keywords

CARBAMAZEPINE;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; ENZYME INDUCTION; HUMAN; KINETICS; MAXIMUM PLASMA CONCENTRATION; PHARMACOLOGICAL PARAMETERS; STEADY STATE;

ANTICONVULSANTS; CARBAMAZEPINE; COMPUTER SIMULATION; DRUGS, GENERIC; HUMANS; MODELS, BIOLOGICAL; THERAPEUTIC EQUIVALENCY;

EID: 84878797015     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201845     Document Type: Article

References (15)

1. Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003; 25: 1578-1592. doi:10.1016/S0149-2918(03)80157-1 PubMed
2. Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure. 2006; 15: 165-176. doi:10.1016/j.seizure.2005.12.010 PubMed
3. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007; 48: 464-469. doi:10.1111/j.1528-1167. 2007.01007.x PubMed (Pubitemid 46365174)
4. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology. 2008; 71: 525-530. doi:10.1212/01.wnl.0000319958.37502.8e PubMed
5. Privitera MD. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr. 2008; 8: 113-117. doi:10.1111/j.1535-7511. 2008.00261.x PubMed
6. Bialer M, Midha KK. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia. 2010; 51: 941-950. doi:10.1111/j.1528-1167.2010.02573.x PubMed
7. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006; 61: 246-255. doi:10.1111/j.1365-2125.2005. 02529.x PubMed (Pubitemid 43382623)
8. Zha J, Endrenyi L. Variation of the peak concentration following single and repeated drug administratons in investigations of bioavailability and bioequivalence. J Biopharm Stat. 2007; 7: 191-204. doi:10.1080/10543409708835179
9. Kudriakova TB, Sirota LA, Rozova GI, Gorkov VA. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol. 1992; 33: 611-615. doi:10.1111/j.1365-2125.1992.tb04089.x PubMed
10. Tothfalusi L, Speidl S, Endrenyi L. Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br J Clin Pharmacol. 2008; 65: 110-122. doi:10.1111/j.1365-2125.2007.02984.x PubMed (Pubitemid 350265172)
11. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
12. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-680. doi:10.1007/BF01068419 PubMed
13. Yacobi A, Zlotnick S, Colaizzi JL, Moros D, Masson E, Abolfathi Z, LeBel M, Mehta R, Golander Y, Levitt B. A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine. Clin Pharmacol Ther. 1999; 65: 389-394. doi:10.1016/S0009-9236(99)70132-3 PubMed (Pubitemid 29196541)
14. MHRA. Public Assessment Report: Carbamazepine 100 mg/5 ml Oral Suspension. London, UK: Medicines and Healthcare Products Regulatory Agency; 2008. http://www.mhra.gov.uk/home/groups/pl-a/documents/websiteresources/ con017919.pdf Accessed: September 24, 2012.
15. Yu LX. Approaches to demonstrate bioequivalence of narrow therapeutic index drugs. Meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee; U.S. Food and Drug Administration, Rockville, MD; July 26, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ AdvisoryCommitteeforPharmaceuticalScienceandClinical Pharmacology/UCM266777.pdf. Accessed: September 24, 2012.